Rivastigmine in subcortical vascular dementia: An open 22-month study

Journal of the Neurological Sciences

Volumn 203-204, Issue , 2002, Pages 141-146

  Moretti, Rita ^a,b   Torre, Paola ^a   Antonello, Rodolfo M ^a   Cazzato, Giuseppe ^a   Bava, Antonio ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Behaviour; Cholinesterase inhibition; Executive function; Rivastigmine; Vascular dementia

Indexed keywords

ACETYLSALICYLIC ACID DERIVATIVE; BENZODIAZEPINE; NEUROLEPTIC AGENT; RIVASTIGMINE;

ADULT; AGED; CAREGIVER; CLINICAL ARTICLE; COGNITION; CONFERENCE PAPER; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; SCORING SYSTEM; SPEECH ARTICULATION; STRESS; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; BEHAVIOR; CARBAMATES; CAREGIVERS; CHOLINESTERASE INHIBITORS; DEMENTIA, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PSYCHIATRIC STATUS RATING SCALES; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 0037111361     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00280-0     Document Type: Conference Paper

References (41)

1. Chui H.C. Dementia. A review emphasizing clinicopathologic correlation and brain-behaviour relationships. Arch. Neurol. 46:1989;806-814.
2. Rocca W.A., Hofman A., Brayne C.et al. The prevalence of vascular dementia in Europe: facts and fragments from 1980-1990 studies. EURODEM-Prevalence Research Group. Ann. Neurol. 30:1991;817-824.
3. Skoog I., Nilsson L., Palmertz B.et al. A population-based study of dementia in 85-year olds. N. Engl. J. Med. 328:1993;153-158.
4. Wetterling T., Kanitz R.D., Borgis K.J. The ICD-10 criteria for vascular dementia. Dementia. 5:1994;185-188.
5. Erkinjuntti T. Vascular dementia: challenge of clinical diagnosis. Int. Psychogeriatr. 9:1997;77-83.
6. Pantoni L., Rossi R., Inzitari D.et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J. Neurol. Sci. 175:2000;124-134.
7. Chui H. Dementia Associated with Subcortical Ischemic Vascular Disease. 2001;American Academy, Philadelphia. 2FC.005-89-107.
8. McPherson S.E., Cummings J.L. Neuropsychological aspects of vascular dementia. Brain Cogn. 31:1996;261-282.
9. Looi J.C.L., Sacdev P.S. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology. 53:1999;670-678.
10. Cummings J.L. Fronto-subcortical circuits and human behaviour. Arch. Neurol. 50:1993;873-880.
11. Saito H., Togashi H., Yoshiaka M.et al. Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 22:1995;S257-S259.
12. Togashi H., Matsumoto M., Yoshioka M.et al. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neurosci. Lett. 166:1994;117-120.
13. Kimura S., Saito H., Minami M.et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology. 153:2000;167-187.
14. Togashi H., Kimura S., Matsumoto M.et al. Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke. 27:1996;520-526.
15. Scremin O.U., Li M.G., Scremin A.M., Jenden D.J. Cholinesterase inhibition improves blood flow in the ischemic cerebral cortex. Brain Res. Bull. 42:1997;59-70.
16. Gottfries C.G., Blennow K., Karlsson I., Wallin A. The neurochemistry of vascular dementia. Dementia. 5:1994;163-167.
17. Wallin A., Blennow K., Gottfries C.G. Neurochemical abnormalities in vascular dementia. Dementia. 1:1989;120-130.
18. Tohgi H., Abe T., Kimura M.et al. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer type dementia. J. Neural Transm. 103:1996;1211-1220.
19. Nordberg A., Svensson A.L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Safety. 19:1998;465-480.
20. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer disease. Neurochem. Res. 25:2000;1185-1190.
21. Weinstock M. Selectivity of cholinesterase inhibition. CNS Drugs. 12:1999;307-323.
22. Mesulam M., Guillozet A., Shaw P., Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol. Dis. 9:2002;88-93.
23. Corey-Bloom J.et al. for the ENA-713 B352 Study Group A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int. J. Geriatr. Psychopharmacol. 1:1998;55-65.
24. Rösler M., Anand R., Cicin-Sain A.et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 318:1999;633-638.
25. Farlow M., Anand R., Messina J. Jr., Hartman R., Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur. Neurol. 44:2000;234-241.
26. Kumar V., Anand R., Messina J., Hartman R., Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease with concurrent vascular risk factors. Eur. J. Neurol. 7:2000;159-169.
27. Moretti R., Torre P., Antonello R.M., Cazzato G. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow up. Eur. J. Neurol. 8:2001;361-362.
28. Romàn G.C., Tatemichi T.K., Erkinjuntti T.et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 43:1993;250-260.
29. Erkinjuntti T., Ketonen L., Sulkava R., Vuorialho M., Palo J. CT in the differential diagnosis between Alzheimer's disease and vascular dementia. Acta Neurol. Scand. 75:1987;262-270.
30. Folstein M., Folstein S., McHugh P. Mini-Mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198.
31. Teng E.L., Chui H.C. The Modified Mini-Mental State (3MS) examination. J. Clin. Psychiatry. 48:1987;214-328.
32. Manos P.J. The utility of the ten-point clock test as a screen for cognitive impairment in general hospital patients. Gen. Hosp. Psych. 8:1997;469-476.
33. Wechsler D. Wechsler Adult Intelligence Scale-R-manual. 1981;Psychological Corp. New York, NY.
34. Katz S., Ford A.B., Moscowitz R.W., Jackson B.A., Jaffe M.W. Studies of illness in the aged: the index of ADL, a standardized measure of biological and psychosocial function. JAMA. 185:1963;914-919.
35. Lawton M.P., Brody E.M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 9:1969;179-189.
36. Hughes C.P., Berg L., Ganziger W.L., Coben L.A., Martin R.L. A new clinical scale for the staging of dementia. Br. J. Psychiatry. 15:1982;211-214.
37. Cummings J.L., Mega M., Gray K.et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 44:1994;2308-2314.
38. Greene J.G., Smith R., Gardiner M., Timburg G.C. Measuring behavioural disturbance of elderly demented in patients in the community and its effects on relatives: a factor analytic study. Age Ageing. 11:1982;121-126.
39. Venneri A., Shanks M.F., Staj R.T., Pestell S.J., Forbes K.E., Gemmell H.G.et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. NeuroReport. 13:2002;83-96.
40. Sachdev P.S., Brodaty H., Looi J.C. Vascular dementia: diagnosis, management and possible prevention. Med. J. Aust. 170:1999;81-85.
41. Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Damaraju C.V. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 359:2002;1283-1290.